Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Clinical trials

A revolution in obesity treatment

Nature Medicine volume 29, pages 2406–2408 (2023)Cite this article

Subjects

Mounting evidence, including the recent (and unprecedented) phase 2 data on retatrutide, supports a role for incretin hormone agonists in treating obesity. But with great power comes great responsibility.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Weight loss with second-generation obesity pharmacotherapies.

References

  1. Jastreboff, A. M. et al. N. Engl. J. Med. 389, 514–526 (2023).

    Article  CAS  PubMed  Google Scholar 

  2. Rosenstock, J. et al. Lancet 402, S0140–6736 (2023).

    Article  PubMed  Google Scholar 

  3. Nogueiras, R., Nauck, M. A. & Tschöp, M. H. Nat. Metab. 5, 933–944 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Wilding, J. P. H. et al. N. Engl. J. Med. 384, 989–1002 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Davies, M. et al. Lancet 397, 971–984 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Jastreboff, A. M. et al. N. Engl. J. Med. 387, 205–216 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Garvey, W. T. et al. Lancet 402, 613–626 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Le Roux, C. Diabetes https://doi.org/10.2337/db23-51-OR (2023).

    Article  Google Scholar 

  9. Wharton, S. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2302392 (2023).

    Article  PubMed  Google Scholar 

  10. Knop, F. K. et al. Lancet 402, 705–719 (2023).

    Article  CAS  PubMed  Google Scholar 

  11. Saxena, A. R. et al. JAMA Netw. Open. 6, e2314493 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Aroda, V. R. et al. Lancet 402, 693–704 (2023).

    Article  CAS  PubMed  Google Scholar 

  13. Frias, J. P. et al. Lancet 402, 720–730 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ildiko Lingvay & Shubham Agarwal

  2. Peter O’Donnell Jr School of Public Health, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ildiko Lingvay

Authors
  1. Ildiko Lingvay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shubham Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ildiko Lingvay.

Ethics declarations

Competing interests

I.L. received grants paid to the Institution from Novo Nordisk, Pfizer, Merck, Sanofi, Boehringer Ingelheim and Mylan; and received consulting fees and covered travel expenses from Novo Nordisk, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Sanofi, Boehringer Ingelheim, Zealand, Bayer, Intercept, Valeritas, Structure, Carmot, Shionoghi, Mediflix and WebMD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lingvay, I., Agarwal, S. A revolution in obesity treatment. Nat Med 29, 2406–2408 (2023). https://doi.org/10.1038/s41591-023-02538-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02538-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing